Baidu
map

Cell & NEJM:全球癌症基因组图谱计划又一研究突破 阐明致死性肾癌的发病机制

2015-11-09 佚名 生物谷

最近,发表在国际杂志the New England Journal of Medicine上的一篇研究论文中,来自从事癌症基因组图谱(The Cancer Genome Atlas)研究计划的科学家通过进行研究,对第二种常见类型的肾癌的两种类型进行了分子特性的分析,并且对这种常见类型的肾癌进行了不同的分类。 每年乳头状肾细胞癌 (Papillary renal cell carcinoma)

最近,发表在国际杂志the New England Journal of Medicine上的一篇研究论文中,来自从事癌症基因组图谱(The Cancer Genome Atlas)研究计划的科学家通过进行研究,对第二种常见类型的肾癌的两种类型进行了分子特性的分析,并且对这种常见类型的肾癌进行了不同的分类。

每年乳头状肾细胞癌 (Papillary renal cell carcinoma)在常见肾癌中的发病率就占到了15%至20%,长期以来这种肾癌被分为1型和2型,但研究者对于引发乳头状肾细胞癌发生的遗传和分子原因知之甚少,而正因为此也一直没有有效的疗法来帮助治疗乳头状肾细胞癌。

文章中,研究者Hui Shen博士表示,乳头状肾细胞癌为科学家们提出了一个特殊的问题,即在某些病人中,疾病虽然没有任何痛感,但却已经广泛扩散于患者的肾脏中了,而在其他病例中,单一的损伤或许是极度恶性的;本文研究中研究者不仅为临床医生们提供了其所需的基于临床结论的研究数据,而且还为开发新型靶向疗法来更好地治疗乳头状肾细胞癌亚型提供希望。

这项研究中,研究人员通过对161名患者的肿瘤组织进行基因组分析,结果发现1型和2型的乳头状肾细胞癌在分子和基因组上并不相同,而且可以被认为是两种完全分离不同的疾病,而2型的乳头状肾细胞癌也分为三种不同的亚型,每一种亚型都具有不同的分子改变和特性。其中一种2型乳头状肾细胞癌的主要特点为DNA甲基化或超甲基化的出现,DNA甲基化是DNA分子的一种修饰,其可以帮助控制基因被开启或关闭,一旦出任何差错就是导致肿瘤的发生;研究者指出,新型的2型乳头状肾细胞癌,即CpG岛甲基化表型是所有类型的头状肾细胞癌中总体存活率最低的亚型,而且这种亚型还和病人机体代谢基因直接改变相关,这些改变都会引发CpG岛甲基化表型肿瘤细胞经历代谢改变,从而促进肿瘤细胞快速生长并且保持活性。

研究者表示,CpG岛甲基化表型样本和乳头状肾细胞癌早期发生相关,而且是最具有致死性的,因此利用分子标志物有效地区分各种亚型的分子特性或可为科学家和临床医生们提供一种有力的工具对多种类型患者进行早期诊断,并且早日采取有效的措施来遏制疾病的发生。

本文的研究工作是癌症基因组图谱计划近日的又一力作,上个月该研究小组还在NEJM上发表了一篇分析乳腺浸润性小叶癌发生机制的研究论文,同日他们还在国际著名杂志Cell上发表了一篇文章,在Cell这篇文章中,研究人员阐明了前列腺癌发生的遗传背景。最后研究者Laird表示,癌症基因组图谱研究对于癌症研究的影响是不可估量的,该计划联合了成百上千名科学家们来进行大规模出色的癌症研究,相信通过后期大量的研究可以获取更多有效的数据来帮助指导临床上癌症的研究,同时也帮助开发新型的癌症疗法。

原文出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2066992, encodeId=a45b2066992ad, content=<a href='/topic/show?id=2ec9e133569' target=_blank style='color:#2F92EE;'>#癌症基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71335, encryptionId=2ec9e133569, topicName=癌症基因)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Fri Jan 08 15:10:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083792, encodeId=edfa2083e92a6, content=<a href='/topic/show?id=285be342772' target=_blank style='color:#2F92EE;'>#研究突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73427, encryptionId=285be342772, topicName=研究突破)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Sun Sep 04 18:10:00 CST 2016, time=2016-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688071, encodeId=809a16880e11f, content=<a href='/topic/show?id=0857418256a' target=_blank style='color:#2F92EE;'>#基因组图谱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41825, encryptionId=0857418256a, topicName=基因组图谱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b0628453628, createdName=124987cdm35暂无昵称, createdTime=Sat Jan 02 10:10:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869238, encodeId=c6dd186923873, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Feb 15 07:10:00 CST 2016, time=2016-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959494, encodeId=c6bf195949458, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Dec 02 00:10:00 CST 2015, time=2015-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568247, encodeId=7970156824eef, content=<a href='/topic/show?id=569d8644eb9' target=_blank style='color:#2F92EE;'>#致死性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86447, encryptionId=569d8644eb9, topicName=致死性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae1815335551, createdName=andy2092, createdTime=Wed Nov 11 04:10:00 CST 2015, time=2015-11-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2066992, encodeId=a45b2066992ad, content=<a href='/topic/show?id=2ec9e133569' target=_blank style='color:#2F92EE;'>#癌症基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71335, encryptionId=2ec9e133569, topicName=癌症基因)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Fri Jan 08 15:10:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083792, encodeId=edfa2083e92a6, content=<a href='/topic/show?id=285be342772' target=_blank style='color:#2F92EE;'>#研究突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73427, encryptionId=285be342772, topicName=研究突破)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Sun Sep 04 18:10:00 CST 2016, time=2016-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688071, encodeId=809a16880e11f, content=<a href='/topic/show?id=0857418256a' target=_blank style='color:#2F92EE;'>#基因组图谱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41825, encryptionId=0857418256a, topicName=基因组图谱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b0628453628, createdName=124987cdm35暂无昵称, createdTime=Sat Jan 02 10:10:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869238, encodeId=c6dd186923873, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Feb 15 07:10:00 CST 2016, time=2016-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959494, encodeId=c6bf195949458, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Dec 02 00:10:00 CST 2015, time=2015-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568247, encodeId=7970156824eef, content=<a href='/topic/show?id=569d8644eb9' target=_blank style='color:#2F92EE;'>#致死性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86447, encryptionId=569d8644eb9, topicName=致死性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae1815335551, createdName=andy2092, createdTime=Wed Nov 11 04:10:00 CST 2015, time=2015-11-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2066992, encodeId=a45b2066992ad, content=<a href='/topic/show?id=2ec9e133569' target=_blank style='color:#2F92EE;'>#癌症基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71335, encryptionId=2ec9e133569, topicName=癌症基因)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Fri Jan 08 15:10:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083792, encodeId=edfa2083e92a6, content=<a href='/topic/show?id=285be342772' target=_blank style='color:#2F92EE;'>#研究突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73427, encryptionId=285be342772, topicName=研究突破)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Sun Sep 04 18:10:00 CST 2016, time=2016-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688071, encodeId=809a16880e11f, content=<a href='/topic/show?id=0857418256a' target=_blank style='color:#2F92EE;'>#基因组图谱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41825, encryptionId=0857418256a, topicName=基因组图谱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b0628453628, createdName=124987cdm35暂无昵称, createdTime=Sat Jan 02 10:10:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869238, encodeId=c6dd186923873, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Feb 15 07:10:00 CST 2016, time=2016-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959494, encodeId=c6bf195949458, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Dec 02 00:10:00 CST 2015, time=2015-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568247, encodeId=7970156824eef, content=<a href='/topic/show?id=569d8644eb9' target=_blank style='color:#2F92EE;'>#致死性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86447, encryptionId=569d8644eb9, topicName=致死性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae1815335551, createdName=andy2092, createdTime=Wed Nov 11 04:10:00 CST 2015, time=2015-11-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2066992, encodeId=a45b2066992ad, content=<a href='/topic/show?id=2ec9e133569' target=_blank style='color:#2F92EE;'>#癌症基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71335, encryptionId=2ec9e133569, topicName=癌症基因)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Fri Jan 08 15:10:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083792, encodeId=edfa2083e92a6, content=<a href='/topic/show?id=285be342772' target=_blank style='color:#2F92EE;'>#研究突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73427, encryptionId=285be342772, topicName=研究突破)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Sun Sep 04 18:10:00 CST 2016, time=2016-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688071, encodeId=809a16880e11f, content=<a href='/topic/show?id=0857418256a' target=_blank style='color:#2F92EE;'>#基因组图谱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41825, encryptionId=0857418256a, topicName=基因组图谱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b0628453628, createdName=124987cdm35暂无昵称, createdTime=Sat Jan 02 10:10:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869238, encodeId=c6dd186923873, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Feb 15 07:10:00 CST 2016, time=2016-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959494, encodeId=c6bf195949458, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Dec 02 00:10:00 CST 2015, time=2015-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568247, encodeId=7970156824eef, content=<a href='/topic/show?id=569d8644eb9' target=_blank style='color:#2F92EE;'>#致死性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86447, encryptionId=569d8644eb9, topicName=致死性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae1815335551, createdName=andy2092, createdTime=Wed Nov 11 04:10:00 CST 2015, time=2015-11-11, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2066992, encodeId=a45b2066992ad, content=<a href='/topic/show?id=2ec9e133569' target=_blank style='color:#2F92EE;'>#癌症基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71335, encryptionId=2ec9e133569, topicName=癌症基因)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Fri Jan 08 15:10:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083792, encodeId=edfa2083e92a6, content=<a href='/topic/show?id=285be342772' target=_blank style='color:#2F92EE;'>#研究突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73427, encryptionId=285be342772, topicName=研究突破)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Sun Sep 04 18:10:00 CST 2016, time=2016-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688071, encodeId=809a16880e11f, content=<a href='/topic/show?id=0857418256a' target=_blank style='color:#2F92EE;'>#基因组图谱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41825, encryptionId=0857418256a, topicName=基因组图谱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b0628453628, createdName=124987cdm35暂无昵称, createdTime=Sat Jan 02 10:10:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869238, encodeId=c6dd186923873, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Feb 15 07:10:00 CST 2016, time=2016-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959494, encodeId=c6bf195949458, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Dec 02 00:10:00 CST 2015, time=2015-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568247, encodeId=7970156824eef, content=<a href='/topic/show?id=569d8644eb9' target=_blank style='color:#2F92EE;'>#致死性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86447, encryptionId=569d8644eb9, topicName=致死性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae1815335551, createdName=andy2092, createdTime=Wed Nov 11 04:10:00 CST 2015, time=2015-11-11, status=1, ipAttribution=)]
    2015-12-02 智智灵药
  6. [GetPortalCommentsPageByObjectIdResponse(id=2066992, encodeId=a45b2066992ad, content=<a href='/topic/show?id=2ec9e133569' target=_blank style='color:#2F92EE;'>#癌症基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71335, encryptionId=2ec9e133569, topicName=癌症基因)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Fri Jan 08 15:10:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083792, encodeId=edfa2083e92a6, content=<a href='/topic/show?id=285be342772' target=_blank style='color:#2F92EE;'>#研究突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73427, encryptionId=285be342772, topicName=研究突破)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Sun Sep 04 18:10:00 CST 2016, time=2016-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688071, encodeId=809a16880e11f, content=<a href='/topic/show?id=0857418256a' target=_blank style='color:#2F92EE;'>#基因组图谱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41825, encryptionId=0857418256a, topicName=基因组图谱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b0628453628, createdName=124987cdm35暂无昵称, createdTime=Sat Jan 02 10:10:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869238, encodeId=c6dd186923873, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Feb 15 07:10:00 CST 2016, time=2016-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959494, encodeId=c6bf195949458, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Dec 02 00:10:00 CST 2015, time=2015-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568247, encodeId=7970156824eef, content=<a href='/topic/show?id=569d8644eb9' target=_blank style='color:#2F92EE;'>#致死性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86447, encryptionId=569d8644eb9, topicName=致死性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae1815335551, createdName=andy2092, createdTime=Wed Nov 11 04:10:00 CST 2015, time=2015-11-11, status=1, ipAttribution=)]

相关资讯

Science:老蛋白的新角色:致癌

近日,刊登在国际著名杂志Science上的一篇研究论文中,来自纪念斯隆-凯特琳癌症研究中心等处的研究人员通过研究表示,一种将正常细胞的分子内容物在细胞间隔运输的已知蛋白可以通过刺激关键的生长控制途径诱导细胞具有癌性。通过寻找名为PI3K/AKT信号通路的调节子,研究者们在致癌过程中发现了蛋白RAB35,信号通路PI3K/AKT会促进细胞生存、生长以及增殖,而且在癌细胞中处于高度活性的状态。研究者D

Nature:最热华人科学家丁莉博士绘制12种癌症遗传突变景观图

来自华盛顿大学医学院的科学家们通过检测12种主要的癌症类型,鉴别出了127个似乎驱动了机体众多肿瘤发生与发展的多次突变基因。这一研究发现为设计出新的诊断工具及更个体化的癌症治疗创造了条件。相关论文发表在著名科学期刊《自然》(Nature)杂志上。 论文的资深作者是华盛顿大学基因研究所的丁莉(Li Ding)博士,其早年毕业于复旦大学,是世界著名的基因科学家。近期汤森•

PNAS:报道明星癌基因NRAS的4个新亚型

RAS癌基因参与人类肿瘤的发生发展,它最初是在急性转化性逆转录病毒实验中,从Harvey、Kirsten两株大鼠肉瘤病毒中克隆出的转化基因,自1982年Weinberg等人发现人膀胱癌细胞系中有活化的H-RAS基因后,引起了人们对RAS癌基因在人类肿瘤发生、发展中所起作用的极大关注。经十余年研究认为,RAS癌基因参与细胞生长和分化的调控,参与多种肿瘤的形成与发展。RAS基因家族成员:Kirsten

Baidu
map
Baidu
map
Baidu
map